Diamond Giant Sri Ramakrishan Branches into Pharma Industry

Gems News: Shree Ramkrishna Exports, a name long associated with sparkling diamonds, has taken a dramatic leap into the pharmaceutical sector with the launch of Kriam Pharma. This move marks a significant diversification for the company, shifting from gemstones to health care. The announcement was made from Surat, where the company unveiled its plans and roadmap for entering this critical domain.

Shree Ramkrishna Exports founder Tej Dholakia unveiling Kriam Pharma signaling its ambition to deliver affordable medicines nationwide
Image Credit: Shree Ramkrishna Exports

A Mission with Wide Reach

Kriam Pharma, as declared by founder Tej Dholakia, aims to bring affordable medicines to the masses — targeting 20,000 towns and villages across India in its initial phase. This Gems News report reveals that the goal is full national coverage by 2030, with over 3,500 direct and indirect jobs expected to be created in the process. The company is also exploring export opportunities to emerging markets where demand for dependable, quality pharmaceuticals is high.

Product Focus and Strategy

Kriam Pharma’s product range will focus on key therapeutic segments: anti-diabetic, cardiac care, gastrointestinal, pain management, dermatological, vitamins and minerals, and anti-infectives.To start, the company will depend on contract development and manufacturing organisations (CDMOs) — essentially outsourcing production — before moving into its own manufacturing in a later phase.

Why This Matters

The Indian pharmaceutical landscape is vast yet uneven. Many rural or semi-urban areas still lack consistent access to affordable, high-quality medicines. With Kriam Pharma, Shree Ramkrishna Exports is trying to bridge that gap. If successful, this could pressure other pharma players to lower costs, improve availability, and boost transparency. Also, as medicines are a major part of household health expenditure, any move that lowers the price burden has ripple effects across public health.

Possible Challenges Ahead

Transitioning from diamonds to pharmaceuticals is not just about shifting one’s product lines; it involves regulatory compliance, supply chain rigour, quality standards, trust building, and huge capital investment for manufacturing facilities. Also, reaching remote towns and villages involves logistic hurdles, cold chain (where needed), and trust in last-mile delivery. Moreover, competing with established pharma companies in both domestic and export markets will demand strong brand credibility and cost efficiencies.

Over the past decade, several non-healthcare groups have moved into pharma, but many have struggled with scaling up quality and trust. For Shree Ramkrishna Exports, the diamond legacy may provide strong brand recognition, but what counts now will be sustained performance in health outcomes, pricing, supply consistency, and regulatory approvals.

This is more than a business gambit — it is a promise of change. For a company backed by decades of craftsmanship in diamonds, Kriam Pharma could be its boldest cut yet — shaping futures not through brilliance, but through healing.

For the latest on Shree Ramkrishna Exports, keep on logging to Gems News.